Faculty Profile

Olwen Hahn
Section of Hematology / Oncology
Associate Professor of Medicine
Referring Physician Access Line: 1-877-DOM-2730

Academic Interests

Dr. Hahn specializes in adult hematology/oncology focusing on the treatment of breast and genitourinary malignancies. She is an Executive Officer for the National Cancer Institute-funded oncology research organization, the Cancer and Leukemia Group B and in this role oversees the development of national clinical trials in breast, respiratory, and genitourinary malignancies.

Clinical Interests

Breast cancer, Renal Cancer, Bladder Cancer, Prostate Cancer, and Testicular Cancer


  • Hahn O and Salgia R, Novel Therapies for Lung Cancer, Hematology Oncology Clinics of North America, 2005:19:2:343-368.
  • Hahn O, Stadler WM. Sorafenib, Curr Opin Oncol. 2006 Nov;18(6):615-21.
  • Hahn O and Salgia R, Non-Receptor Tyrosine Kinase Inhibitors in Lung Cancer, Current Medicinal Chemistry, Anticancer Agents Med Chem 2007 Nov;7(6):633-42.
  • O Hahn, C Yang, M Medved, G Karczmar, E Krisner, T Karrison, B Manchen, M Mitchell, M Ratain, W Stadler. Dynamic contrast enhanced MRI: a pharmacodynamic study of sorafenib in metastatic renal cell carcinoma: results of randomized, phase II trial. J Clin Oncol. 2008 Oct 1;26(28):4572-8.
For a complete list of publications click here:


  • BA, 1997, Princeton University, Molecular Biology
  • MD, 2001, Emory University, School of Medicine, Medicine
  • Residency, 2004, The University of Chicago Medical Center, Internal Medicine
  • Fellowship, 2007, The University of Chicago Medical Center, Hematology/Oncology